Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OCTAGON: A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients With Generalized Myasthenia Gravis Treated With Ravulizumab

NCT07221838 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07221838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07221838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OCTAGON: A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients With Generalized Myasthenia Gravis Treated With Ravulizumab
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Phase 4
Overall status
Recruiting
Start date
March 4, 2026
Completion date
August 27, 2027
Enrollment
75 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis, gmg